NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: UNICHEMLAB · data 2026-10-31
Unichem Laboratories Limited
In plain words
Price: 29.6% below its 52-week high of ₹687.2.
Delivery: 38.2% of traded shares were kept for delivery over the last 10 sessions, against 36.8% over the last 60.
Latest results: a net profit of ₹41 cr for the quarter ended Jun 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹2,308 cr |
| Net profit (last 12 months) | ₹305 cr |
| Sales growth, 3 years (yearly) | 18.1% |
| Profit growth, 3 years (yearly) | — |
At a glance
Promoters 70.2% (unchanged in a year), pledged 0.0%, institutions 12.1%.
P/E 11.2, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 9.8%, ROCE -0.5%, operating margin 4.6%: how much profit it earns on the money it uses.
Debt/equity 0.18, Profit growth — and sales growth 18.1% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Thin operating margin (4.6%).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
Q1 FY27
Revenue: 632.62
Net Profit: 41.47
Operating Margin: 11.1
EPS: 6.61 turned to profit
Q1 FY27
राजस्व: 632.62
नेट लाभ: 41.47
परिचालन मार्जिन: 11.1
EPS: 6.61 लाभ में बदल गया
Q1 FY27
મહેસૂલ: 632.62
નેટ લાભ: 41.47
કાર્યકારી માર્જિન: 11.1
EPS: 6.61 લાભમાં બદલાયું
Written by AI from the filed numbers and checked against them. Not a recommendation.
Smart-money activity
15/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 10/30: Delivery 34.7% over the last 20 sessions vs 18.5% in the 40 before (1.88x); shares delivered per day 0.31x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results
- 11 Aug 26Results Q1 FY27 results: turned to profit vs a year ago +7.5% next session
- 22 May 26Results Q4 FY26 results: profit −79.4% YoY -2.1% next session
- 5 Feb 26Results Q3 FY26 results: profit +356.9% YoY -5.1% next session
- 11 Nov 25Results Q2 FY26 results: turned to loss vs a year ago +3.8% next session
- 4 Aug 25Results Q1 FY26 results: turned to loss vs a year ago -11.2% next session
- 22 May 25Results Q4 FY25 results: turned to profit vs a year ago +5.5% next session
- 6 Feb 25Results Q3 FY25 results: profit −31.1% YoY +0.9% next session
- 13 Nov 24Results Q2 FY25 results: turned to profit vs a year ago +1.9% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹633 cr | ₹41 cr | — | 11.1% | 6.61 |
| Mar 2026 | ₹575 cr | ₹11 cr | -79.4% | 8.3% | 1.55 |
| Dec 2025 | ₹521 cr | ₹264 cr | +356.9% | 8.6% | 37.54 |
| Sept 2025 | ₹579 cr | ₹-12 cr | -139.0% | 11.4% | -1.69 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 70.22% | 70.22% | 70.22% | 70.22% |
| Foreign institutions (FII) | 2.70% | 0.90% | 1.00% | 0.99% |
| Domestic institutions (DII) | 9.40% | 10.46% | 10.63% | 10.74% |
| Mutual funds | 8.65% | 9.32% | 9.07% | 9.17% |
| Retail investors | 13.06% | 13.46% | 13.35% | 13.32% |
| Number of shareholders | 26,164 | 25,347 | 23,386 | 23,267 |
Common questions
What was Unichem Laboratories Limited's latest quarterly profit?
Unichem Laboratories Limited reported a net profit of ₹41 cr for the quarter ended Jun 2026, on revenue of ₹633 cr.
How much do promoters hold in Unichem Laboratories Limited?
Promoters held 70.22% of Unichem Laboratories Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Unichem Laboratories Limited debt-free?
Its latest reported debt-to-equity ratio is 0.18.
What is Unichem Laboratories Limited's P/E ratio?
About 11.2, based on the last 12 months' earnings and a price of ₹483.75 (data 2026-10-31).
What is the 52-week high and low of Unichem Laboratories Limited?
The 52-week high is ₹687.2 and the 52-week low is ₹278.2.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Unichem Laboratories Limited | ₹483.75 | ₹3,404 cr | 11.2 | — | 9.8% | -0.5% | 0.18 | +3.4% |
| Aarti Drugs Limited | ₹435.2 | ₹3,977 cr | 20.8 | — | 13.4% | 13.2% | 0.37 | -12.1% |
| Kwality Pharmaceuticals Ltd | ₹3,475.3 | ₹3,604 cr | 44.5 | — | 22.6% | 31.4% | 0.39 | +98.9% |
| Shukra Pharmaceuticals Ltd. | ₹74.87 | ₹3,295 cr | 96.6 | — | 28.9% | 31.3% | 0.06 | +78.1% |
| Ind-Swift Laboratories Ltd. | ₹368.2 | ₹3,195 cr | 38.2 | 2.2 | 3.4% | -0.2% | 0.01 | +260.3% |
| Solara Active Pharma Sciences Ltd. | ₹632.6 | ₹3,043 cr | 84.2 | 2.1 | -0.6% | 5.9% | 0.55 | +6.1% |
Compare UNICHEMLAB with AARTIDRUGS in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open UNICHEMLAB in NSE Scanner →